The minimal inhibitory concentrations of Rodogyl (composite tablet of metronidazole and spiramycin), metronidazole-spiramycin mixture, spiramycin, metronidazole, and tetracycline were determined for selected putative periodontopathic microorganisms. Rodogyl was active against almost all strains, including Bacteroides species and the anaerobic spirochetes. Synergism of the component drugs in the Rodogyl combination was noted against Propionibacterium species. Spiramycin activity against Actinomyces species was enhanced in the presence of metronidazole.
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The minimal inhibitory concentrations of Rodogyl (composite tablet of metronidazole and spiramycin), metronidazole-spiramycin mixture, spiramycin, metronidazole, and tetracycline were determined for selected putative periodontopathic microorganisms. Rodogyl was active against almost all strains, including Bacteroides species and the anaerobic spirochetes. Synergism of the component drugs in the Rodogyl combination was noted against Propionibacterium species. Spiramycin activity against Actinomyces species was enhanced in the presence of metronidazole.
Rodogyl is the proprietary name for a composite tablet of two antimicrobial agents, spiramycin and metronidazole. Spiramycin is a macrolide antibiotic belonging to the same group as erythromycin. It has been used widely in Europe and to a limited extent in Canada for the treatment of a variety of dental infections. It has been reported to be effective in treatment of periodontal infections, including marginal gingivitis, periodontal abscesses, necrotic ulcerative gingivitis, and periodontitis (5, 14) . Like other macrolide antibiotics, spiramycin is active against grampositive bacteria and less active against gramnegative bacteria, although Bordetella pertussis and Neisseria species are usually susceptible. Metronidazole is a synthetic nitroimidazole compound with bactericidal activity against a broad spectrum of anaerobic bacteria. It has been shown to be effective in treating acute necrotic ulcerative gingivitis (1) . More recently it has been used experimentally in the treatment of periodontitis (12) .
The combination of spiramycin and metronidazole has been reported to have a synergistic effect on the bucco-dental flora (7) . Ten times less spiramycin and 30 times less metronidazole were required for the same inhibitory effect against anaerobic bacteria when both drugs were combined as compared to their use alone. However, no systematic evaluation of the antimicrobial susceptibility patterns of pure cultures of putative periodontopathic bacteria to these two drugs has been carried out. This note reports the minimal inhibitory concentrations (MICs) obtained when potential periodontopathic bacteria were challenged with the two antimicrobial agents, spiramycin and metronidazole, singly and in combination. Data from such a study will provide an indication of the efficacy -of Rodogyl in eliminating potential periodontopathic bacteria. Comparisons were also made with tetracycline, an antibiotic frequently advocated for use against periodontal disease (5) .
Standard assay bacteria used for comparison were Sarcina lutea ATCC 9341 for spiramycin and Clostridium perfringens for metronidazole. The susceptibilities of these two species to the antimicrobial agents were mutually exclusive (i.e., S. lutea was not inhibited by metronidazole and C. perfringens was not inhibited by spiramycin). The selection of putative periodontopathic bacteria was based on literature reports of their predominant presence in diseased sites (4, 5, 10) . The cultures used were Actinobacillus actinomycetemcomitans ATCC 33384, Actinomyces naeslundii ATCC 12104, Actinomyces viscosus WVU627 (from R. Ellen, University of Toronto), Bacteroides asaccharolyticus ATCC 27067, and Fusobacterium nucleatum (from Stock Culture Collection, Department of Microbiology and Immunology, McGill University). Our own isolates from the sulci of periodontally diseased patients included Bacteroides melaninogenicus subsp. intermedius 81, Bacteroides melaninogenicus subsp. melaninogenicus 94, Peptostreptococcus sp., Propionibacterium sp., and Treponema a, d, and e strains. Inocula consisted of 0.5 ml of a culture of bacteria in the early-logarithmic growth phase per assay tube, each containing a total volume of 5 ml.
The The MIC values for the standard assay bacteria and the potential periodontopathic bacteria are summarized in Table 1 . As may be seen from the data, except for the standard assay organisms S. lutea and C. perfringens, the metronidazole-spiramycin mixture and Rodogyl gave essentially similar results on the putative periodontopathic bacterial strains. Why Rodogyl was less effective than the metronidazole-spiramycin mixture on the standard assay organisms-even after repeated bioassays-cannot be explained easily. Perhaps the selective susceptibilities of S. lutea and C. perfringens to the two antimicrobial agents (spiramycin and metronidazole) may affect their biological response to the drugs in the presence of filler material in the composite pill.
An MIC value of 8 ,ug/ml was chosen as the threshold value for resistance to the antimicrobial drugs tested based on the established antibiotic concentrations achieved in body fluids with optimal therapy. Metronidazole has been reported in serum at 8 ,ug/ml (5), tetracycline in gingival fluid at 8 ,ug/ml, and spiramycin in saliva at 8.9 g/ml (6). Thus, organisms resistant to We found the Rodogyl was active in vitro against putative periodontopathic bacterial species with one exception, Peptostreptococcus sp. However, against the more commonly reported groups of periodontopathic bacteria, such as Bacteroides species (2, 13) and the anaerobic spirochetes (3, 9, 11) , Rodogyl was very effective.
The in vivo effectiveness of antibiotics is dependent not only on in vitro activity but also on ability to get to the site of action, viz., the gingiva and the crevicular fluid in the case of periodontal disease. No good and reliable data exist at the present time on the bioavailability of Rodogyl in tissues, such as in serum, crevicular fluid, and gingiva. Until this knowledge is available, on the basis of these in vitro studies, Rodogyl is only acceptable as an alternative to tetracycline in the treatment of periodontal disease.
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